Inquiry Basket
Loading ......
African horse sickness (AHS) is one of the most devastating and highly lethal viral diseases affecting equids, characterized by severe cardiovascular and respiratory complications that result in a mortality rate capable of exceeding 90% in fully susceptible horse populations. The etiological agent, the African horse sickness virus (AHSV), is a member of the genus Orbivirus within the family Sedoreoviridae (formerly classified under the Reoviridae family). Endemic to the tropical and subtropical regions of sub-Saharan Africa, the virus is primarily transmitted by hematophagous midges of the genus Culicoides. Beyond the catastrophic animal welfare implications, AHS imposes a massive economic burden on the agricultural and equine industries, severely restricting the international trade, competition, and movement of equids. Recently, global scientific interest in AHSV has surged, fueled by the accelerating impacts of climate change on vector distribution and the urgent need for advanced, biosurety-compliant prophylactic strategies.
The AHSV virion is a non-enveloped, highly structured, and complex infectious particle. Its architecture comprises a ten-segment, double-stranded RNA (dsRNA) genome encapsidated within a concentric, double-layered protein shell. The segmented genome encodes seven distinct structural proteins (VP1 through VP7) and at least four non-structural proteins (NS1, NS2, NS3, and NS3a). The structural integrity, cellular entry mechanisms, and pathogenic lifecycle of the virus are inextricably linked to the diverse biological functionalities of these tightly organized viral proteins.
Figure 1. Schematic representation of the AHSV virion.
(Source: Dennis SJ, et al. 2019)
The outer capsid of the AHSV virion is principally composed of two major proteins: VP2 and VP5. VP2 is the most genetically and antigenically variable protein among the nine currently recognized AHSV serotypes. Structurally, it forms prominent triskelion-shaped domains on the virion's surface. As the outermost and most exposed structural protein, VP2 is the principal determinant of the virus's serotype and acts as the primary target for the host's virus-neutralizing antibodies. Furthermore, VP2 plays an indispensable role in the initial stages of cellular infection, specifically mediating viral attachment to host cell receptors. Recent structural and virological insights indicate that VP2 is highly sensitive to the biochemical microenvironment; for instance, proteases found in the saliva of the Culicoides vector can cleave VP2, generating highly infectious sub-viral particles that facilitate enhanced transmission. Beneath the VP2 triskelions lies the VP5 protein layer, which organizes into globular trimers. VP5 is an amphipathic protein that functions cooperatively with VP2. Following the endocytosis of the virion, the progressively acidic environment of the host endosome triggers a profound conformational change in VP5. This change exposes membrane-permeabilizing domains that disrupt the endosomal membrane, facilitating the release of the transcriptionally active viral core directly into the host cell cytoplasm.
The inner core of the virion, contrasting sharply with the variable outer shell, is highly conserved across all nine AHSV serotypes. It consists of two major structural proteins, VP7 and VP3, alongside three minor enzymatic proteins. VP7 forms the prominent, robust surface layer of the inner core, arranged in highly stable hexameric and trimeric configurations. Because of its exceptional degree of genetic and antigenic conservation across all lineages of the virus, VP7 is highly immunogenic and serves as the primary group-specific antigen. Consequently, recombinant VP7 is the universal diagnostic target of choice in commercially available competitive enzyme-linked immunosorbent assays (cELISAs) utilized for global AHS surveillance and regulatory testing. Beneath the densely packed VP7 layer, the VP3 protein forms the rigid subcore scaffold—a proteinaceous matrix that completely encloses the dsRNA genome segments and the tightly associated transcription complex.
The three minor structural proteins—VP1, VP4, and VP6—are tethered to the inner surface of the VP3 scaffold, functioning as a highly coordinated molecular machine. VP1 acts as the RNA-dependent RNA polymerase (RdRp), directly driving viral transcription and genome replication. VP4 functions as a capping enzyme with methyltransferase activity, ensuring the structural stability, protection, and translation efficiency of the newly synthesized viral mRNA transcripts. Finally, VP6 operates as an RNA helicase, unwinding the tightly coiled dsRNA duplexes to feed single strands into the VP1 polymerase during the transcription cycle. Together, this intricate assembly of structural proteins orchestrates a highly efficient replication cycle that culminates in massive viral progeny production, rapid host cell lysis, and the severe, systemic endothelial damage that defines clinical African horse sickness.
Historically, African horse sickness has been confined predominantly to sub-Saharan Africa, punctuated by occasional, self-limiting epizootic excursions into North Africa, the Middle East, and the Iberian Peninsula. However, in the contemporary era, the epidemiological landscape of vector-borne orbiviruses is being profoundly and irreversibly altered by global climate change. The geographical distribution, population density, seasonal activity, and survival rates of the primary biological vector, Culicoides imicola, as well as other competent Culicoides species, are extraordinarily sensitive to microclimatic variables, notably ambient temperature, humidity, and precipitation patterns.
Climatic shifts and sustained global warming have systematically facilitated the steady northward expansion of these hematophagous midges into temperate zones previously deemed entirely unsuitable for their survival. Warmer global temperatures do more than merely expand the geographic boundaries of the vectors; they significantly amplify their vectorial capacity. Elevated ambient temperatures drastically shorten the extrinsic incubation period of the virus within the midge's gut and salivary glands, allowing the insect to become highly infectious much more rapidly following a viremic blood meal. Furthermore, milder and shorter winters enable the successful overwintering of both infected adult midges and the virus itself within local microhabitats, leading to the early, explosive onset of transmission cycles in the subsequent spring.
The European continent and parts of temperate Asia are increasingly recognized by international veterinary bodies as high-risk, vulnerable zones for a catastrophic AHS outbreak. This anxiety is firmly grounded in recent empirical evidence; the unprecedented emergence and rapid spread of related Culicoides-borne pathogens, such as Bluetongue virus (BTV) serotypes 8 and 3, and the Schmallenberg virus throughout Northern and Western Europe over the last two decades, serve as a glaring harbinger. These outbreaks unequivocally demonstrate that indigenous European Culicoides species (most notably those belonging to the C. obsoletus and C. pulicaris complexes) are highly competent at transmitting exotic orbiviruses. Should AHSV be introduced into these newly hospitable, immunologically naive environments—whether via the transport of subclinically infected equids, wind-borne dispersion of midges across water bodies, or other anthropogenic routes—the resulting epizootic would trigger staggering mortality rates in the highly susceptible horse population, precipitating devastating socioeconomic consequences.
The looming threat of wide-scale geographic expansion has radically intensified the global scientific discourse surrounding prophylactic strategies for AHSV. For decades, disease control in endemic regions has relied heavily upon polyvalent live-attenuated vaccines (LAVs). While LAVs are highly effective at inducing robust, long-lasting cellular and humoral immunity, their continued use in modern veterinary medicine is fraught with significant biosafety and regulatory concerns. The primary hazard associated with LAVs is the inherent virological risk of gene segment reassortment between co-circulating vaccine strains and wild-type field viruses, a phenomenon that can spawn novel, highly virulent reassortant strains. Additionally, LAVs have been historically implicated in causing clinical disease symptoms in immunocompromised or genetically sensitive equids. Most critically for international commerce, traditional LAVs do not permit the differentiation of naturally infected animals from vaccinated ones.
Figure 2. Scheme of the immune response that can be used to differentiate vaccinated and naturally infected animals.
(Source: Jayaraman S, et al. 2016)
Consequently, modern virological research has decisively pivoted toward the engineering of next-generation, molecularly defined vaccines that strictly comply with the DIVA (Differentiating Infected from Vaccinated Animals) principle. DIVA compliance is absolutely essential for the safe international movement of horses, as it allows regulatory authorities to serologically confirm that an animal is free from active, wild-type infection without being confounded by vaccine-induced antibody responses.
Recent breakthroughs have been dominated by recombinant vaccine technologies. For instance, recombinant viral vectors utilizing Modified Vaccinia virus Ankara (MVA) expressing key immunogenic AHSV proteins—specifically the outer capsid protein VP2 and the non-structural protein NS1—have shown immense promise. Incorporating NS1 alongside the serotype-determining VP2 has been shown to elicit broad, cross-protective cytotoxic T-cell responses in various in vivo models, bridging the gap between specific humoral immunity and broad cellular defense.
Another highly innovative and promising avenue of contemporary research involves the Disabled Infectious Single Animal (DISA) vaccine platform. Developed utilizing advanced reverse genetics technology, the DISA approach generates a replication-competent but dissemination-defective orbivirus. By introducing targeted, precise deletions in essential viral genes (such as the NS3 gene, which is critical for viral release from the host cell), researchers have successfully created DISA vaccines for all nine individual AHSV serotypes. Extensive recent testing in murine models, particularly IFNAR (-/-) mice, has demonstrated that these multivalent DISA vaccines induce powerful, serotype-specific neutralizing antibodies without any risk of reversion to virulence or secondary transmission by the midge vector. Crucially, the deliberate deletion of the NS3 protein inherently acts as a perfect negative molecular marker; vaccinated animals will not produce anti-NS3 antibodies, providing an elegant and flawless DIVA companion diagnostic capability. These modern platforms represent a monumental leap forward, successfully marrying the potent immunogenicity of live-virus vaccination with the impeccable safety and diagnostic profiles required by modern international veterinary regulations.
References
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| AHSV | DMAB-CS24316 | Mouse Anti-AHSV Monoclonal antibody, clone FY026 | Mouse | IgG2a | ELISA | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| AHSV NS3 | DAGA-3531 | Recombinant Protein African horse sickness virus 2 S10, E.coli | E. coli | His | N/A | Inquiry |
| DAGA-3532 | Recombinant Protein African horse sickness virus 2 S10, Baculovirus | Baculovirus | His | N/A | Inquiry | |
| DAGA-3533 | Recombinant Protein African horse sickness virus 2 S10, Mammalian cell | Mammalian cells | His | N/A | Inquiry |
Loading ......
